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Gastrointestinal stromal tumors (GISTs) are mesenchymal tumors of gastrointestinal tract arising from the interstitial cell of Cajal. The term was coined by Mazur and Clark in 1983, and later on it was observed that these tumors overexpress tyrosine kinase receptors due to mutation in genes C-kit (CD117 or CD34) or platelet-derived growth factor receptor A (PDGFRA) detected on immunohistochemistry.\[[@ref1]\] The incidence of GIST is 10--20 cases per million population and mostly seen in patients older than 50 years, accounting for \<1% of all gastrointestinal tumors.\[[@ref2]\] Most of the tumors are seen in the stomach and rarely in the mesentery. Complete R0 resection ensures better chances of survival.\[[@ref3][@ref4]\] Imatinib, a tyrosine kinase inhibitor drug, has a major role to play postoperatively, as there is a lack of response of GIST to radiotherapy or chemotherapy.
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A 32-year-old male presented to us with a history of gradual abdominal distension for 5 months and acute pain of 2 days duration. There was no history of any previous investigations or any hospital admissions. Physical examination showed pulse rate of 82/min, blood pressure of 120/80 mmHg, and respiratory rate of 22/min. Abdominal examination revealed a huge tender mass occupying the periumbilical area and both lumbar regions. Abdominal ultrasound showed 18 cm × 15 cm mass with solid and cystic components arising from small bowel mesentery with loops of bowel adherent to it. A clinical diagnosis of mesenteric cyst with small bowel obstruction was made. Emergency laparotomy done for acute abdomen showed a huge mass of 18 cm × 15 cm arising from small bowel mesentery, with involvement of few loops of proximal ileum 20 cm in length as shown in [Figure 1](#F1){ref-type="fig"}. Debulking of the tumor was done with resection of the above loops of ileum. Small part of tumor (2 cm × 1 cm) could not be removed as it was encasing the superior mesenteric vessels.

![Gastrointestinal stromal tumors' mass excised](NJS-23-71-g001){#F1}

Histopathology of the tumor revealed GIST as shown in [Figure 2](#F2){ref-type="fig"}, with mitosis index of 17/50 high power fields (HPF) and CD117 positive. The patient postoperatively received tablet imatinib 400 mg/day. Twelve months postoperatively, the patient was re-explored as he developed recurrence with distant metastasis in the liver and peritoneum confirmed on contrast-enhanced computed tomography (CT) scan, but the same could not be re-excised. The patient survived 6 months after the second re-exploration while on tablet imatinib.

![High power slide of gastrointestinal stromal tumors](NJS-23-71-g002){#F2}
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GISTs are mostly seen in stomach (60%), followed by small bowel (30%), rectum (5%), and esophagus (5%). GISTs are rarely seen in mesentery, omentum, or retroperitoneum, comprising \<1% of GISTs.\[[@ref2]\] GIST present as lump in abdomen, pain due to tumor necrosis or rupture, and rarely as nontraumatic hemoperitoneum due to bleeding from the tumor mass. Abdominal ultrasound and CT scan are the main diagnostic investigations. On CT scan, mesenteric GIST is a well-defined lobular mass showing heterogeneous contrast enhancement with areas of hypodensity.\[[@ref2]\] Surgery with R0 resection is the mainstay of treatment that shall ensure better prognosis with a good survival. Apart from this, the tumor size \>5 cm, presence of tumor necrosis, mitosis \>5/50 HPF, positive resection margins, and distant metastasis are all poor prognostic indices. Our patient had a large tumor (18 cm × 15 cm), mitosis of 17/50 HPF, central necrosis, and positive resection margins which must have resulted in early recurrence with peritoneal and liver metastasis, which are the common sites of spread in malignant GIST.\[[@ref5]\] Ninety-five percentage of GIST are C-Kit positive (CD117 or CD34) while 5% are PDGFRA-positive.\[[@ref1]\] Targeted chemotherapy with imatinib, a tyrosine kinase inhibitor drug, used postoperatively is believed by some to prevent or delay recurrences and improve survival.\[[@ref3]\] However, there is no consensus on this issue. Some believe that there is no proof that treatment with imatinib improves survival.\[[@ref4]\] In our case, we cannot conclude about the definite postoperative benefits of imatinib. This subject requires further research. The malignant potential of GIST varies from benign to malignant with benign having a 5-year survival of 95% whereas in the malignant type, it is 21%.\[[@ref1][@ref3]\] In recurrent disease, the median survival is 9--12 months.\[[@ref1][@ref3]\] In our case, it was 6 months.
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Mesenteric GIST, being a rare entity, can be clinically mistaken for mesenteric cyst and can present as acute abdomen due to tumor necrosis. In cases with short duration of abdominal mass arising from mesentery, one has to keep in mind the possibility of mesenteric GIST. Large mass (\>5 cm), incomplete resection margins, mitosis \>5 HPF, and central necrosis are all poor indices for survival and result in high recurrences.
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